Have any feedback? I’d love to hear you from - connect with me on LinkedIn. 📣

Bayer's Sunharbo (asundexian) wins FDA approval for secondary stroke prevention via Factor XIa inhibition
Small molecule, cardiovascular, Factor XIa inhibitor, stroke, anticoagulant, secondary stroke prevention - Read more

Deerfield Management, Amazon Web Services partner to provide genAI and cloud services to Deerfield's portfolio companies
Research collaboration, AI/ML, drug discovery, cloud technology, digital health - Read more

Third Rock Ventures, Funnel Biosciences collaborate on AI antibody discovery for multiple targets, up to $2.16B
Research collaboration, antibody, AI/ML, drug discovery, milestone payments - Read more

iDEL Therapeutics, Daiichi Sankyo collaborate on multi-drug conjugate preclinical research for solid tumors
Research collaboration, oncology, antibody-drug conjugate, drug discovery, small molecule - Read more

Science 2 Sales is the outbound engine for companies selling into biotech & pharma. We handle the market intelligence, prospect scoring, email sequences, LinkedIn outreach, and cold calling - so your sales team inherits a full calendar of qualified meetings.

Built by biopharma BD & sales reps, exclusively for biopharma commercial teams. It’s the platform and service we wish we had years ago.

Learn more and book a free strategy call on our website.

Veradermics completes Ph3 program for VDPHL01 (minoxidil) in male androgenetic alopecia with strong 12-month hair growth data
Small molecule, dermatological, minoxidil, androgenetic alopecia, extended-release formulation - Read more

Mirum Pharmaceuticals' (brelovitug) meets Ph3 primary endpoint, advancing FDA bid for chronic hepatitis D treatment
Antibody, infectious disease, monoclonal antibody, hepatitis D, antiviral, HBsAg target - Read more

J&J's Caplyta (lumateperone) scores second Ph3 win in bipolar I mania, supporting FDA label expansion bid
Small molecule, neurological, lumateperone, bipolar disorder, dopamine receptor antagonist - Read more

PepGen's (PGN-EDODM1) Ph2 data show 46.5% splicing correction in myotonic dystrophy type 1
Antisense oligonucleotide, neurological, myotonic dystrophy type 1, splicing correction, rare muscle disease - Read more

Beam Therapeutics prepares FDA biologics license application for (risto-cel) after Ph1/2 sickle cell disease pivotal success
Cell therapy, hematological disease, base editing, sickle cell disease, BCL11A target, fetal hemoglobin induction - Read more

Oyster Therapeutics raises $60M Series A extension for tau-targeting brain drug development
Neurological, protein degrader, Alzheimer disease, tau-targeting, preclinical - Read more

Neobe raises $6.8M seed round to develop engineered bacteria breaking tumour barriers
Oncology, engineered bacteria, platform technology, solid tumors, preclinical, immunotherapy - Read more

Sanyou Biopharmaceuticals raises ~$15M Series C, advancing AI-driven drug discovery platforms
AI-driven, antibody, drug discovery, platform technology, CRO - Read more

Venomics AI raises $2.7M pre-seed funding to expand AI-powered venom-based drug discovery
AI/ML platform, drug discovery, venom-based therapeutics, computational biology, preclinical - Read more

Phillips Medisize expands UK inhalation manufacturing footprint with new Chippenham site investment
Inhalation drug-device combination, respiratory, manufacturing expansion, operational - Read more

WuXi AppTec removed from US Chinese military companies list following court victory
Contract manufacturing, biosecurity, regulatory, competitive - Read more

AstraZeneca acquires Omniose, securing bioconjugation platform to advance bacterial vaccine development
Conjugate vaccine, infectious disease, strategic, major transaction - Read more

Do you offer a biotech/pharma-focused product or service?

Or looking to get investor/analyst interest on your budding start-up?

Considering sponsoring TLDR Biotech to get in-front of an engaged audience of biotech & pharma-focused professionals.

Just reply to this email* or message me on LinkedIn to learn more.

*If you’re reading this on the web version, email [email protected]

Vertex lays off 78 Crinetics Pharmaceuticals staffers amid $10B acquisition integration
Small molecule, endocrine disease, major transaction, operational - Read more

Coherus Oncology cuts 30% of staff to focus on esophageal cancer; Gyre Therapeutics lays off workers post-Cullgen acquisition
Monoclonal antibody, oncology, cost reduction, protein degrader - Read more

FDA orders class-wide GLP-1 label update adding rare eye disease risk, impacting Eli Lilly, Novo drugs
GLP-1 receptor agonist, ophthalmology, regulatory, competitive - Read more

AbCellera discontinues (ABCL575) development past Ph1, exits OX40 ligand program for atopic dermatitis
Antibody, autoimmune, monoclonal antibody, atopic dermatitis, OX40/OX40L target - Read more

Have comments/questions/complaints about this newsletter?
Send me an email - I want your brutally honest feedback. 📝

If you find the content useful and think a colleague would too, please share TLDR Biotech with them! ♻️

And lastly - connect with me on LinkedIn!

Disclaimer: Content, news, research, tools, and mention of stock or tradeable securities are for educational and illustrative purposes only and do not imply a recommendation or solicitation to buy or sell a particular security or to engage in any particular investment strategy. Read the full terms & conditions here